[go: up one dir, main page]

DK3193867T3 - Okulære formuleringer til lægemiddelfremføring og beskyttelse af øjets forreste segment - Google Patents

Okulære formuleringer til lægemiddelfremføring og beskyttelse af øjets forreste segment Download PDF

Info

Publication number
DK3193867T3
DK3193867T3 DK15841620.6T DK15841620T DK3193867T3 DK 3193867 T3 DK3193867 T3 DK 3193867T3 DK 15841620 T DK15841620 T DK 15841620T DK 3193867 T3 DK3193867 T3 DK 3193867T3
Authority
DK
Denmark
Prior art keywords
eye
protection
front segment
ocular formulations
medicinal production
Prior art date
Application number
DK15841620.6T
Other languages
English (en)
Inventor
David P Bingaman
Paul G Chaney
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Application granted granted Critical
Publication of DK3193867T3 publication Critical patent/DK3193867T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15841620.6T 2014-09-17 2015-09-17 Okulære formuleringer til lægemiddelfremføring og beskyttelse af øjets forreste segment DK3193867T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Publications (1)

Publication Number Publication Date
DK3193867T3 true DK3193867T3 (da) 2021-04-06

Family

ID=55453708

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15841620.6T DK3193867T3 (da) 2014-09-17 2015-09-17 Okulære formuleringer til lægemiddelfremføring og beskyttelse af øjets forreste segment

Country Status (19)

Country Link
US (6) US9814702B2 (da)
EP (2) EP3878449B1 (da)
JP (3) JP6657193B2 (da)
KR (2) KR102450020B1 (da)
CN (2) CN106999476B (da)
AU (2) AU2015317531B2 (da)
CA (1) CA2958315A1 (da)
DK (1) DK3193867T3 (da)
ES (2) ES3010497T3 (da)
HU (1) HUE053852T2 (da)
IL (2) IL282504B (da)
MA (1) MA56220A (da)
MX (2) MX383792B (da)
NZ (1) NZ767710A (da)
PL (1) PL3193867T3 (da)
PT (1) PT3193867T (da)
RU (2) RU2768652C1 (da)
WO (1) WO2016044671A1 (da)
ZA (1) ZA201701303B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3193867T (pt) * 2014-09-17 2021-03-09 Panoptica Inc Formulações oculares para administração de fármaco e proteção do segmento anterior do olho
CN110933933B (zh) * 2018-07-18 2022-12-27 温州医科大学 一种治疗近视的方法及制备药物的应用
CN113164551A (zh) * 2018-10-24 2021-07-23 雅利斯塔制药公司 脂联素肽模拟物制剂
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2792997A (en) * 1997-05-26 1998-12-30 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ATE340786T1 (de) * 2000-11-28 2006-10-15 Pfizer Prod Inc Salze eines 4-isothiazolcarboxamids und ihre verwendung als anti-hyperproliferationsmittel
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
EP1814540A2 (en) * 2004-11-16 2007-08-08 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
JP5583145B2 (ja) * 2009-03-03 2014-09-03 アルコン リサーチ, リミテッド レセプターチロシンキナーゼ阻害(RTKi)化合物の眼への送達のための薬学的組成物
AU2010282698A1 (en) 2009-08-11 2012-03-15 Allergan, Inc. Isothiozoles for treating conditions of the eye
BR112012007345A2 (pt) * 2009-09-30 2015-09-01 Univ California E Vitapath Genetics Inc Formulação, métodos para preparar a formulação, para determinar uma quantidade de cofator para um indivíduo, para determinar um risco ou uma predisposição para uma condição remediável por cofator em um indivíduo, auxiliado por computador para fornecer um plano de recomendação nutricional personalizado para um indivíduo e comercial para fornecer um plano de recomendação nutricional personalizado para um indivíduo, ácido nucleico isolado ou um complemento do mesmo, arranjo, e, sistema de computador
EP2595628A1 (en) * 2010-07-19 2013-05-29 Bayer HealthCare LLC Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
KR101845107B1 (ko) * 2010-08-17 2018-04-03 오에이치알 파마서티컬, 인코포레이티드 스쿠알라민 안약 제제
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
WO2013074625A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Suspensions of cyclosporin a form 2
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
AU2014239252B2 (en) 2013-03-14 2017-07-06 Panoptica, Inc. Ocular formulations for drug-delivery to the posterior segment of the eye
PT3193867T (pt) * 2014-09-17 2021-03-09 Panoptica Inc Formulações oculares para administração de fármaco e proteção do segmento anterior do olho

Also Published As

Publication number Publication date
NZ767710A (en) 2023-09-29
US9814702B2 (en) 2017-11-14
KR20170058976A (ko) 2017-05-29
EP3878449B1 (en) 2024-10-30
CN106999476A (zh) 2017-08-01
JP7176042B2 (ja) 2022-11-21
CN113209000B (zh) 2025-05-13
HUE053852T2 (hu) 2021-07-28
IL282504A (en) 2021-06-30
US10183014B2 (en) 2019-01-22
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
US20180078531A1 (en) 2018-03-22
PT3193867T (pt) 2021-03-09
EP3193867B1 (en) 2021-01-20
ES2863601T3 (es) 2021-10-11
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
PL3193867T3 (pl) 2021-07-12
US20210275501A1 (en) 2021-09-09
JP2021121624A (ja) 2021-08-26
EP3878449A1 (en) 2021-09-15
AU2015317531B2 (en) 2020-11-19
MX2017003436A (es) 2017-07-28
IL251019A0 (en) 2017-04-30
JP2017527600A (ja) 2017-09-21
KR20220137157A (ko) 2022-10-11
US20160206599A1 (en) 2016-07-21
NZ729142A (en) 2023-08-25
EP3193867A4 (en) 2018-05-02
RU2768652C1 (ru) 2022-03-24
US20190314343A1 (en) 2019-10-17
CN106999476B (zh) 2021-05-04
JP6890692B2 (ja) 2021-06-18
CA2958315A1 (en) 2016-03-24
MA56220A (fr) 2022-04-20
ES3010497T3 (en) 2025-04-03
MX383792B (es) 2025-03-14
ZA201701303B (en) 2021-07-28
US20160074371A1 (en) 2016-03-17
JP6657193B2 (ja) 2020-03-04
US9623011B2 (en) 2017-04-18
AU2021200997A1 (en) 2021-03-11
RU2017112930A3 (da) 2019-04-11
KR102450020B1 (ko) 2022-09-30
IL282504B (en) 2022-08-01
WO2016044671A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
IL251019B (en) 2021-05-31
RU2704810C2 (ru) 2019-10-31
RU2017112930A (ru) 2018-10-17
JP2020079274A (ja) 2020-05-28
KR102555091B1 (ko) 2023-07-13
US20240277674A1 (en) 2024-08-22
MX2021006070A (es) 2021-07-06

Similar Documents

Publication Publication Date Title
GB2568579B (en) Ophthalmic drug compositions
GB201913962D0 (en) Ophthalmic drug compositions
DK3356313T3 (da) 2-perfluorhexyloktan til oftalmisk indgivelse
IL249643A0 (en) Ophthalmic composition
DK3191502T3 (da) Målrettet indgivelse af tertiært aminholdige lægemiddelstoffer
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3169328T3 (da) Quinolinderivater til behandling af inflammationssygdomme
PT3500255T (pt) Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
PL3179982T3 (pl) Sposób zwiększenia biodostępności i/lub przedłużenia działania oftalmicznego leku
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
EP3528737A4 (en) MEDICAL SUPPORT
FR3041114B1 (fr) Articulation de lunettes et lunettes correspondantes
EP3094291A4 (en) Schlemm's canal stent-sieve
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
EP3397995A4 (en) LENS
IL282504A (en) Ocular formulations for drug administration and protection of the front part of the eye
DK3185867T3 (da) Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
DK3452093T3 (da) Ophthalmiske sammensætninger
MA44987A (fr) Formulations de médicaments améliorées
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3122743T3 (da) Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
PT3439548T (pt) Tonómetro portátil melhorado
DK3229811T3 (da) Forebyggelse og behandling af betændelseslidelser
DK3519050T3 (da) Sammensætninger til behandling af oftalmiske sygdomme